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Abstract
In endemic regions, Lyme disease is a potential health threat to dogs. Canine Lyme disease
manifests with arthritis-induced lameness, anorexia, fever, lethargy, lymphadenopathy and, in
some cases, fatal glomerulonephritis. A recent study revealed that the regional mean for the
percentage of seropositive dogs in the Northeast of the USA is 11.6%. The outer surface protein C
(OspC) of Lyme disease spirochetes is an important virulence factor required for the establishment
of infection in mammals. It is a leading candidate in human and canine Lyme disease vaccine
development efforts. Over 30 distinct ospC phyletic types have been defined. It has been
hypothesized that ospC genotype may influence mammalian host range. In this study, Ixodes
scapularis ticks collected from the field in Rhode Island were assessed for infection with B.
burgdorferi. Ticks were fed on purpose bred beagles to repletion and infection of the dogs was
assessed through serology and PCR. Tissue biopsies (n = 2) were collected from each dog 49 days
post-tick infestation (dpi) and the ospC genotype of the infecting strains determined by direct PCR
of DNA extracted from tissue or by PCR after cultivation of spirochetes from biopsy samples. The
dominant ospC types associated with B. burgdorferi canine infections differed from those
associated with human infection, indicating a relationship between ospC sequence and preferred
host range. Knowledge of the most common ospC genotypes associated specifically with infection
of dogs will facilitate the rational design of OspC-based canine Lyme disease vaccines and
diagnostic assays.
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Introduction
Borrelia burgdorferi, the primary causative agent of Lyme disease in North America, is
transmitted to mammals through the bite of Ixodes spp. ticks (Burgdorfer et al., 1982;
Benach et al., 1983). In 2009, nearly 38,000 cases of confirmed and probable human Lyme
disease were reported in the United States1. In Europe, additional Borrelia spp., including B.
garinii, and B. afzelii, have been identified and demonstrated to cause Lyme disease
(Baranton et al., 1992; Marconi and Garon, 1992). While the incidence of Lyme disease is
thought to be higher in Europe, estimates of case numbers are not known accurately due to a
lack of uniform reporting criteria. Lyme disease is a potential health threat to dogs in both
North America and Europe (Krupka and Straubinger, 2010; Little et al., 2010). In dogs,
Lyme disease may manifest with arthritis-induced lameness, anorexia, fever, lethargy,
lymphadenopathy and, in some cases, fatal glomerulonephritis (Little et al., 2010). A recent
study revealed that the percentage of seropositive dogs in the Northeast states of the USA
ranges from 7.1% in New York to 19.8% in Massachusetts, with a regional mean of 11.6%
(Bowman et al., 2009). In the Midwest of the USA, this value ranges from < 1% in several
states to 10.2% in Wisconsin, with a regional mean of 4.0% (Bowman et al., 2009).
Strategies to prevent infection in dogs have focused on acaricides and vaccination.
Acaricides are effective at decreasing tick burdens, but do not provide complete protection
and, depending on delivery approach, may require frequent (monthly) applications. While
several Lyme disease vaccines have been licensed for use in dogs, the broad protective
efficacy and ability to induce long term protective immunity is low (Littman et al., 2006;
Earnhart and Marconi, 2008; Marconi and Earnhart, 2010). In a recent study, a multi-strain
B. burgdorferi bacterin vaccine provided protection against tick challenge for 1 year
(LaFleur et al., 2010). However, Borrelia spp. based bacterin vaccines are expensive to
produce and it is difficult to maintain consistent quality. There is a clear and pressing need
for development of subunit vaccines for canine Lyme disease.
Outer surface protein C (OspC) is a 22 kDa surface-exposed lipoprotein (Fuchs et al., 1992)
encoded by a stable and universal 26 kb circular plasmid (Marconi et al., 1993a and b;
Sadziene et al., 1993). OspC is an essential virulence factor that has been postulated to
participate in interactions with tick or host-derived ligands at the tick-host interface that are
required for the establishment of infection (Hovius et al., 2008; Earnhart et al., 2010; Onder
et al., 2012). OspC elicits robust and protective antibody responses, making it an attractive
candidate for vaccine development (reviewed in Earnhart and Marconi, 2008; Marconi and
Earnhart, 2010).
A challenge encountered in efforts to develop OspC as a vaccine is its inherent genetic
diversity (Theisen et al., 1993, 1995; Wilske et al., 1993, 1995; Lagal et al., 2006; Earnhart
and Marconi, 2007c). Over 30 distinct ospC phyletic types have been identified (Seinost et
al., 1999a; Wang et al., 1999; Brisson and Dykhuizen, 2004; Earnhart and Marconi, 2007c).
Immune responses elicited by OspC protective epitopes are ‘phyletic type’ specific
(Earnhart et al., 2005; Buckles et al., 2006; Earnhart and Marconi, 2007b). Hence, a broadly
protective OspC based vaccine must include protective epitopes derived from ospC variants
most commonly associated with mammalian infection. The use of cocktails consisting of
multiple recombinant OspC proteins has not proven effective, possibly due to misdirection
of immune responses to immunodominant epitopes that do not elicit protective antibody
responses (Earnhart and Marconi, 2008; Marconi and Earnhart, 2010). Chimeric
recombinant proteins offer a conceptually promising approach for the development of
1See: http://www.cdc.gov.
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broadly protective vaccines. An octavalent recombinant chimeric protein that consists of
linearepitopes derived from the loop 5 and α helix 5 domains of OspC elicited bactericidal
antibody against strains producing OspC type proteins represented in the vaccine construct
(Earnhart et al., 2007a; Earnhart and Marconi, 2007b and c). This finding indicates that a
chimeric approach to Lyme disease vaccine development is possible.
To facilitate the rational design of a cost effective, broadly protective, OspC based vaccine
intended for use in dogs, it is essential to identify the ospC genotypes most commonly
associated with strains that successfully infect dogs. Towards this goal, field caught Ixodes
scapularis ticks collected from Rhode Island were fed on laboratory raised dogs, tissue
biopsies were collected and the ospC genotype of strains present in tissue and tissue-derived
cultures were determined. The results demonstrate that unique ospC types rarely recovered
from human Lyme disease patients predominate in canine infections. This observation
indicates that a chimeric OspC based Lyme disease vaccine intended for use in dogs must
consist of different component epitopes than a vaccine intended for use in humans. The data
have significant implications for the design of a broadly protective OspC based vaccine for
use in dogs.
Methods and materials
Tick collection and analysis
Adult I. scapularis ticks were collected in southern Rhode Island in the spring of 2008 by
flagging. The percentage of ticks infected with B. burgdorferi was determined by direct
fluorescent microscopy using standard methods and labeled anti-B. burgdorferi antibody
(Nicholson et al., 1996).
Infestation of dogs with field caught ticks
All procedures were conducted in compliance with regulations of the Animal Welfare Act.
The study protocol (#KZ-1201e-2005-08pxm) was reviewed and approved (16 May 2008)
by Pfizer’s Animal Care and Use Committee prior to the start of the study. Fifteen purpose-
bred beagles of both sexes (7 males, 8 females; 9 to 10 weeks of age; Marshall
Bioresources) were assigned identification numbers and divided into four groups, designated
T01 (n = 4), T02 (n = 4), T03 (n = 4) and T04 (n = 3). The dogs were fitted with Elizabethan
collars and housed in one-over115 one condominium style cages. The dogs were
acclimatized to the collars by having them wear the collars for increasing amounts of time
over several days.
Thirteen days prior to tick infestation, serum was collected from each dog. Dogs in groups
T01, T02, T03 and T04 were infested with 0, 25, 50 or 75 adult I. scapularis ticks,
respectively, using secured infestation chambers placed on each side of the mid-thorax. The
chambers were adhered using Elastikon (Johnson and Johnson). To ensure that the dogs did
not interfere with the chambers, each was fitted with a lightweight jacket. Ticks were fed to
repletion, removed and serum samples (5 mL) collected on days −13, 21, 35, 49, 63, 77 and
92. Skin biopsies (2 mm) were collected at 49 dpi. Seroconversion was assessed with the
4DX SNAP test (IDEXX) and C6 titers determined on a fee for service basis by IDEXX
using a semi-quantitative ELISA (Lyme Quant C6 Test).
To cultivate spirochetes from infected dogs, approximately half of each 2 mm skin biopsy
was placed in 6 mL BSK-H media (Sigma) supplemented with 6% rabbit serum (Sigma) and
Borrelia antibiotic cocktail (phosphomycin, amphotericin B and rifampicin; Sigma) and the
cultures maintained at 37 °C under 5% CO2. Clonal populations were obtained from the
cultures by sub surface plating (Sung et al., 2001). Colonies were excised from the plates
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and placed in BSK-Hmedia for cultivation. The uncloned isolates recovered from the tissue
biopsies were designated as DRI indicating that they originated from dogs (D) that were
infected using ticks collected in Rhode Island (RI). DRI is followed by a portion of the
identifier number that was assigned to each dog. Lower case letters that follow the number
indicate a specific clone derived from the uncloned isolate by subsurfacing plating as
detailed above.
DNA extraction and PCR
DNA was extracted from the remaining half of each skin biopsy using the Qiagen DNeasy
Kit and from cultures of B. burgdorferi clonal populations as described previously
(McDowell et al., 2001). The ospC and flaB genes were amplified by PCR using DNA (100
ng) extracted from tissues and from the supernatant of boiled B. burgdorferi cell lysates.
PCR was performed using standard conditions, GoTaq polymerase (Promega) and the
following primers; ospC-F1 5’-
GACGACGACAAGATTGAATACATTAAGTGCAATATTAATGAC-3’ and ospC-R1 5’-
GAGGAGAAGCCCGGTTTACAAATTAATCTTATAATATTGATCTT AATTAAGG-3’.
The primers used to amplify flaB have been described previously (Zhang and Marconi,
2005). The amplicons were assessed by agarose gel electrophoresis and ethidium bromide
staining.
The PCR products obtained from amplification of DNA extracted from tissues were excised
from the gels using the Qiagen Gel Extraction Kit, cloned into the pET46EK/LIC vector
(Novagen) and the plasmids were propagated in Escherichia coli NovaBlue cells (Novagen).
The resulting E. coli colonies were screened for ospC by PCR using cell lysates obtained by
boiling E. coli colonies in water. Portions of the ospC PCR positive colonies were
transferred into Luria-Bertani broth media (2 mL) and grown overnight. Cells were
harvested by centrifugation and plasmids were extracted using the Qiagen MiniPrep kit.
PCR amplicons obtained by amplification of ospC from B. burgdorferi colonies were
directly sequenced after purification and were not cloned into a plasmid.
Phylogenetic analysis
DNA sequencing was performed by Eurofins MWG Operon. Phylogenetic analyses were
conducted as described previously (Earnhart and Marconi, 2007c). Neighbor joining trees
were generated using ClustalX 2.0.10 software in the multiple alignment mode with the
default settings and a Gonnet matrix, and were visualized using N-J Plot version 2.2.
Previously determined sequences of known ospC type were included in the analysis in order
to assign type designations to the sequences determined in this study.
Results
Analysis of the prevalence of B. burgdorferi in ticks collected from Rhode Island
Using a standardized direct fluorescent microscopy method (Nicholson et al., 1996), 52% of
the I. scapularis ticks field-collected in southern Rhode Island during the Spring of 2008
were infected with B. burgdorferi. Tick infection rates (TIRs) for Spring-collected adult
female I. scapularis collected at the same set of sites in southern Rhode Island ranged from
50-70% from 2004–2009 (average 55.4%). Relatively high TIRs in nymphal (~25%) and
adult (55%) I. scapularis and abundance levels of both developmental stages are consistent
with the high incidence of human Lyme disease cases in Rhode Island (~17 per 100,000
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people statewide from 2006 to 20102, with ~50 times more human cases per 100,000 people
in southern Rhode Island towns (T. Mather; unpublished results).
Infection of dogs with B. burgdorferi through tick infestation
Field collected ticks were fed on dogs that had been confirmed to be seronegative at the start
of the study. Since the infection rate in the field collected ticks was 52% and since typically
not all ticks placed on an animal will feed, dogs in groups T02, T03 and T04 were infested
with 25, 50 or 75 ticks. Tick attachment rates ranged from 3% for dog 730173 (group T04)
to 100% for dog 729485 (group T02). The average tick attachment rate for animals in
groups T02, T03 and T04 was 46%. Serum samples were collected −13, 21, 35, 49, 63, 77
and 92 dpi and evaluated for antibodies against B. burgdorferi and Anaplasma
phagocytophilum/A. platys antigens using the +SNAP 4DX test (Table 1). Ten of eleven
tick-infested dogs were positive for B. burgdorferi and all of the tick188 infested dogs were
positive for A. phagocytophilum/A. platys. Anaplasma infection was not verified using other
SNAP independent methods. The dog in group T04 that was antibody negative for B.
burgdorferi was removed from the study and was not analyzed further, bringing the total
number of dogs in the study to 14. Dogs in group T01 (not tick infested, negative controls
dogs) remained negative by the SNAP test for B. burgdorferi and A. phagocytophilum/A.
platys over the course of the study. Antibody titers against the VlsE derived C6 peptide were
determined using the Lyme C6 Quantitative Antibody test. The minimum and maximum
titers for each group at each time point and the geometric means are listed in Table 1. Most
dogs in groups T02, T03 and T04 displayed significant antibody titers starting at day 35
post-infestation. The number of ticks that were fed on each dog did not appear to influence
antibody titer. The presence of spirochetes in tissue of dogs that were seropositive was
demonstrated using PCR. All seropositive dogs yielded ospC and flaB amplicons of the
predicted size, whereas all seronegative dogs were PCR negative for both genes (data not
shown). Infection status was further evaluated by cultivation of spirochetes from tissue
biopsies. All tick infested dogs (except the single dog that was removed from group T04, as
discussed above) yielded positive cultures while dogs in group T01 were culture negative.
Analysis of ospC diversity in strains found in culture positive dog tissues
To determine the ospC genotype of strains in the skin of dogs exposed to ticks, ospC was
PCR amplified from DNA extracted from skin biopsies. The resulting amplicons were
cloned and sequenced. Five or more E. coli colonies for each cloned amplicon were selected
for ospC sequence determination. The resulting sequences were aligned and a dendrogram
was constructed (Fig. 1). Six of the ten dogs were infected with multiple strains as inferred
from the amplification of multiple ospC types from the DNA extracted from the skin
biopsies (Table 2). ospC types A, B, F, I and N were identified, with types F and N being the
most prevalent (5/10 and 7/10 dogs, respectively).
It is possible that there could have been strains present in the infected tissues that were not
efficiently amplified by PCR. To further define the range of ospC genotypes present in the
infected dogs, uncloned B. burgdorferi cultures derived from the skin biopsies were plated
and clonal populations obtained. ospC was then amplified from individual colonies and the
sequence of the amplicons determined (a dendrogram depicting the sequencing results is
presented in Fig. 2). ospC types that were not detected by direct PCR of tissue biopsies were
identified in 3/6 dogs. Two of the identified ospC types, both of which originated from the
same dog, had not been previously described in the literature. These phyletic types were
designated DRI85a and DRI85e. Other ospC types identified by this approach included
2See: http://www.cdc.gov.
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types E, F, H, I, N, U and T (Table 1). Collectively, a total of 11 different ospC types were
detected in dogs infected with wild caught ticks from Rhode Island.
Discussion
It has been postulated that the ospC genotype of B. burgdorferi may influence strain host
range and, consistent with this hypothesis, only a limited subset of OspC types (A, B, C, D,
I, and K) are most commonly associated with invasive disease in humans (Seinost et al.,
1999a; Buckles et al., 2006; Earnhart et al., 2005). The diversity of ospC types associated
with infection in dogs had not been assessed previously. This is a critical step in efforts to
develop a broadly protective OspC based Lyme disease subunit vaccine for use in dogs and
potentially other companion animals. In this study we determined the ospC genotype of
Lyme disease spirochete strains recovered from dog tissue 49 dpi. Field collected I.
scapularis ticks from Rhode Island were fed on laboratory dogs and the ospC genotype of
strains present in skin were determined at 49 dpi.
A total of 11 different ospC types were identified, with ospC type F being the most
frequently detected (50% of infected dogs). While ospC type F is among the more common
ospC phyletic types found in ticks in Medocino, California (Girard et al., 2009), to date there
is only a single database report of an ospC type F strain that originated from humans. Types
B, N and U, which occur at low frequency in humans (Seinost et al., 1999a and b; Earnhart
and Marconi, 2007c; Brisson et al., 2011), were also detected in the dogs. Two ospC
sequences were determined that differed in sequence by more than 5% from previously
delineated ospC types. A 5% difference in sequence is considered to be sufficient to warrant
the designation of a new ospC type (Earnhart and Marconi, 2007c). These variant ospC
sequences originated from clones derived from the DRI85 isolate and were assigned the
phyletic type designations DRI85a and DRI85e.
It is noteworthy that the dominant ospC types identified in the cultures derived from canine
tissues differed from those most readily detected by direct PCR of the tissue. For example,
whiletype F and type N ospC were directly amplified from most tissue samples, these ospC
types were only detected in a single tissue derived culture. Strains producing OspC types F
and N have growth rates similar to that of strains producing other OspC types, so this
observation is not likely to be due to the inability of type F strains to adapt to in vitro
cultivation conditions. The results presented here are consistent with a previous report that
demonstrated greater B. burgdorferi diversity directly in human tissue samples relative to
cultures derived from the same tissue samples (Liveris et al., 1999). Collectively, these
analyses demonstrate that multiple approaches are required to accurately assess the genetic
diversity of infecting strains.
The diversity observed in this study is consistent with earlier studies that demonstrated the
maintenance of several ospC phyletic types within a local B. burgdorferi population (Wang
et al., 1999; Qiu et al., 2002; Alghaferi et al., 2005; Earnhart et al., 2005; Anderson and
Norris, 2006). In that the ticks used in this study were collected from a single geographic
region, it is possible that strains producing other OspC types that are not well represented in
Rhode Island are also competent to infect dogs. Future analyses, using ticks collected from
other geographic regions will assess this possibility. In spite of this caveat, this study is the
first to demonstrate that ospC types not previously associated with human infection can
infect dogs. The data suggest that an OspC based vaccine intended for use in dogs needs to
be designed to include different epitopes than those being used in the development of a
human OspC-derived chimeric vaccine.
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Conclusions
The ospC genotypes of B. burgdorferi strains that successfully established infection in dogs
after tick infestation were determined. Some unique ospC phyletic types that had not been
previously described were detected. Overall the ospC genotypes most commonly detected in
dogs differed from those that have been demonstrated in humans. These findings have
significant implications for the design of OspC-based canine Lyme disease vaccines and
diagnostic assays.
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Fig 1.
Phylogenetic analysis of OspC sequences amplified directly from skin biopsy samples
collected from dogs after infestation with ticks. ospC was PCR amplified directly from skin
biopsies and the amplicons were cloned into E. coli. Recombinant plasmids were isolated
from several independent colonies for each cloning reaction and the sequence of the inserts
was determined. The nomenclature used for the determined sequences is as described in the
text. Note that individual sequences cloned from a single PCR reaction are differentiated by
a hyphenated number. The translated sequences were aligned and a dendrogram constructed.
ospC type identity was determined by comparative analysis with previously determined
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ospC sequences of known phyletic type. ospC type identity is indicated to the right by
bracketing. The scale bar indicates substitutions per sequence position.
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Fig 2.
Phylogenetic analysis of OspC sequences derived from clonal populations of Borrelia
burgdorferi cultivated from biopsies from dogs. Biopsy samples were placed in media and
spirochetes cultivated. The cultures were sub-surface plated, individual colonies were
picked, ospC was amplified and the ospC sequences determined. The scale bar indicates
substitutions per sequence position.
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Table 2
OspC phyletic types identified in tick infested dogs
Group
Individual animal
identifier number
Designation for tissue
derived isolate
OspC types PCR amplified
directly from tissue
OspC types PCR amplified
from biopsy derived cultures
T01 729451, 729566 None recovered Not applicable Not applicable
729680, 729698
T02 729485 DRI85 A, N U, DRI85a, DRI85e
729663 DRI63 N Not determined
730416 DRI16 A, N E
730203 DRI03 B, F, N H, N
T03 730009 DRI09 I, N Na
730505 DRI05 F E, U
730441 DRI41 B, I, N Not determined
730483 DRI83 F E
T04a 729540 DRI40 F, N E, I, F, T
730173 DRI73 F Not determined
aA third dog originally included in group T04 (not listed above) did not seroconvert and was PCR and culture negative for B. burgdorferi. Only 3%
of the ticks attached to this dog during tick infestation.
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